RABEVA-O
Rabeprazole & Ondansetron Gastro Resistant Tablets comes under the branding RABEVA-O. It is a gastrointestinal medication, that contains two medications Rabeprazole & Ondansetron refers to the combination known as “proton pump inhibitors”. It prevents the gastric proton pump, which is responsible for producing stomach acid, from doing its job. This lessens acid production, treats ulcers, and stops the development of new ulcers. In the group of medications known as anti-emetics, ondansetron works to stop vomiting, stomach ulcers, gastro-oesophageal reflux disease (GERD), heartburn, and erosive oesophagitis. In addition, Rabeprazole & Ondansetron Gastro Resistant Tablets are also used to treat infections caused by Helicobacter pylori and Zollinger-Ellison syndrome.
What are the possible side effects of Rabeprazole and Ondansetron Gastro Resistant Tablets?
As with any medication, Rabeprazole and Ondansetron Gastro Resistant Tablets may have potential side effects. The specific side effects can vary depending on the individual and the doses used. Common side effects associated with Rabeprazole may include headache, diarrhea, abdominal pain, and nausea. Common side effects of Ondansetron can include headache, constipation, dizziness, and fatigue. It’s important to consult your doctor if you experience severe or persistent side effects.
Can Rabeprazole and Ondansetron Gastro Resistant Tablets be taken during pregnancy or breastfeeding?
It’s important to consult with your doctor for personalized advice in these situations. The use of Rabeprazole and Ondansetron Gastro Resistant Tablets during pregnancy or breastfeeding should be discussed with a healthcare professional. Each component of the medication may have different considerations regarding its safety and potential risks.
| Brand Name | RABEVA-O |
|---|---|
| Composition | RABEPRAZOLE- 20MG+ONDANSETRON-4MG |
| Pack Size | 10 X 10 |
You must be logged in to post a review.
Automated page speed optimizations for fast site performance
Reviews
There are no reviews yet.